UK Health secretary Matt Hancock has sought to curb any medicines shortages which could endanger patient health in the event of a ‘no deal’ Brexit from 29 March 2019. Hancock has instructed that the NHS needs to set aside six weeks’ worth of medicines – but according to anti-Brexit campaign group, Best for Britain, this
In a recent statement the MHRA has clarified how the UK’s clinical trials rules will function in partnership with the EU after Britain leaves March next year. “As part of exit negotiations, MHRA is working to ensure that we continue to have the best possible environment in which to support clinical trials,” the agency said.
Lately it has been difficult to not hear, read or see anything Brexit related and it has been clear that it is an event that will undoubtedly alter every industry in the UK, including life sciences. With headlines such as “Sanofi is stockpiling drugs to prepare for a no-deal Brexit” and “EMA cuts back as
Although there have been various warnings about the supply train issues that will happen if a so-called “hard Brexit” occurs, the UK and EU have been unable to refine terms on how drugs will move amongst countries. As a result the NHS is also having to scramble to figure out how to mitigate possible drug
Clinical Professionals will be attending the City & Financial Global’s ‘BREXIT: What does it mean for the Life Sciences’ Summit, which takes place in London on 20th June. The event will examine both short-term and long-term strategies for navigating BREXIT safely and allowing the UK to keep its current status as a leading Life Sciences
Yvette Cleland comments on the latest Clinical Professionals Industry Analytics report, “What do we expect the impact of the EMA leaving the UK to be?” “The Dutch government’s successful bid to host the European Medicines Agency (EMA) has already faced its first hurdle, the temporary offices in which it was proposed to house some staff
By Nikki Doyle, Graduate Academy and Hosted Employee Manager at Clinical Professionals As the Clinical Professionals Graduate Academy Manager, I always encourage our graduates to ask questions to further their knowledge and the one question that comes up with constant regularity is ‘what impact will Brexit have on the clinical research industry?’ Having always